Pre-Made Etanercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F for drug discovery and mechanism of action (MOA) research

Pre-Made Etanercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. It has U.S. Food and Drug Administration (FDA) approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Tumor necrosis factor alpha (TNF¦Á) is the “master regulator” of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.[1]

Etanercept is a fusion protein, It fuses the TNF receptor to the constant end of the IgG1 antibody. Etanercept is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. It is used to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Tumor necrosis factor alpha (TNF¦Á) is the “master regulator” of the inflammatory (immune) response in many organ systems.